EXELIXIS INC (EXEL)
US30161Q1040 - Common Stock
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
Top Buys by Directors: Johnson's $2.6M Bet on EXEL
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
/PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this...
NASDAQ:EXEL, a growth stock which is not overvalued.
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Will EXELIXIS INC Break Out? A Technical Analysis Perspective.
Will EXELIXIS INC breakout?
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
3 Biotech Stocks With the Strongest Clinical Pipelines
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Exelixis Larger Than S&P 500 Component Generac Holdings
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2023.
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
/PRNewswire/ -- The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is...
Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
Exelixis (EXEL) reported positive Phase 3 results for its drug Cabometyx in the treatment of certain neuroendocrine tumors. Read more here.
Oversold Conditions For Exelixis (EXEL)
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue.
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock.
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
Exelixis started at buy at Wainwright on targeted oncology pipeline (NASDAQ:EXEL)
H.C. Wainwright initiates Exelixis with a buy rating, citing its robust pipeline of targeted oncology assets. Read more here.
Noteworthy Thursday Option Activity: MCO, MAXN, EXEL
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.